Singmed dramatically enter CPHI China 2024, manifesting a new breakthrough in local drug delivery technology innovation and mass production

Shanghai, June 19, 2024 - With its breakthrough drug delivery technology, proven mass production experience and facilities, Singmed once again became the focus of industry attention at the 22nd CPHI China 2024.

As the first local company in China to break through patent and technical barriers in the field of dry powder and soft mist inhalation drug delivery devices and successfully pass the in vivo Consistency Evaluation (official BE), Singmed showcased its latest blockbuster products at this exhibition. Including generic Seretide inhaler, generic Ellipta inhaler, soft mist inhaler delivery device, generic Breezhaler inhaler, generic Handihaler inhaler, innovative nasal spray system, etc., demonstrating the innovative strength of Chinese local enterprises in the field of complex drug delivery devices and commercial manufacturing.

For domestic enterprises, Singmed's breakthrough in independent R&D not only means the enhancement of technological autonomy, but also indicates that in the field of inhalation preparations, Chinese enterprises have the ability to break the market monopoly of international giants. Self-developed products can effectively reduce costs, improve access to medicines, and enable more patients to afford high-quality inhalation therapy. At the same time, this will also stimulate the innovation vitality of the domestic medical industry, promote the development of the related inhalation drug industry chain, and lay a solid foundation for the innovation and development of the domestic medical industry.

Mr. Albert Zhao, the founder and Executive Director of Singmed, said: "Singmed is committed to helping local pharmaceutical companies accelerate the substitution of inhalation preparations through technological innovation and large-scale manufacturing, and promote the innovation of drug-device combination products of global partners. We will continue to deepen cooperation with worldwide pharmaceutical companies to promote the further development of drug delivery technology."